Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Rhythm Pharmaceuticals Inc
(NQ:
RYTM
)
41.79
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
41.79
Bid (Size)
41.79 (3)
Ask (Size)
51.50 (1)
Prev. Close
41.79
Today's Range
41.79 - 41.79
52wk Range
15.50 - 52.57
Shares Outstanding
60,140,495
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
March 25, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
March 11, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Performance
YTD
-7.40%
-7.40%
1 Month
-9.45%
-9.45%
3 Month
-15.81%
-15.81%
6 Month
+73.84%
+73.84%
1 Year
+142.97%
+142.97%
More News
Read More
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences
March 06, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Analyst Expectations For Rhythm Pharmaceuticals's Future
February 22, 2024
Via
Benzinga
Preview: Rhythm Pharmaceuticals's Earnings
February 21, 2024
Via
Benzinga
Rhythm Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
January 25, 2024
Via
Benzinga
The Analyst Verdict: Rhythm Pharmaceuticals In The Eyes Of 7 Experts
January 04, 2024
Via
Benzinga
Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan
February 22, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
February 22, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
February 08, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Analyst Expectations for Rhythm Pharmaceuticals's Future
December 07, 2023
Via
Benzinga
Earnings Scheduled For February 22, 2024
February 22, 2024
Via
Benzinga
Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
February 07, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
January 31, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
2 biotechs with promising weight-loss drugs coming
January 16, 2024
Via
MarketBeat
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
January 12, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640
January 04, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates
January 04, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
December 15, 2023
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Sponsors Second Annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) 2023
December 13, 2023
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rare Genetic Diseases Of Obesity-Focused Rhythm Pharma's Bardet-Biedl Syndrome Drug Meets Primary Goal In Pediatric Trial
December 06, 2023
Via
Benzinga
Rhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D Event
December 06, 2023
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
November 13, 2023
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update
November 07, 2023
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Earnings Scheduled For November 7, 2023
November 07, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.